overall survival rates in case of single-station N2 involvement, no extracapsular spread, lymph node ratio <1/3, skip metastases and adjuvant radiochemotherapy, which are the results of common knowledge. They focused on microscopic-N2 (metastasis smaller than 2 mm in size), and found that it was associated with better median and 5-year survival compared with macroscopic-N2 (42 vs 23 months) and (39 vs 21%), respectively (P < 0.0001). Regarding the microscopic-N2 series, the prognosis tended to be better in case of multiple-N2 stations and survival was better in patients benefitting from simple follow-up rather than adjuvant therapy. However, adjuvant therapy was more frequent (84% of microscopic-N2), and the simple follow-up probably concerned unusual patients.
We thank Riquet et al. for their kind and meaningful comments on our manuscript [1, 2] . In an attempt to explain the different prognostic significance of micro-N2 between their study [3] and ours [2] , they have questioned the impact of neoadjuvant therapy (NAT) on micro-N2. In our cohort, the survival of micro-N2 was similar, regardless NAT was given or not [median overall survival (OS): 41 months (95% CI 32.7-49.3) vs 43 months (95% CI 35.26-50.74), P ¼ 0.08, respectively]. This observation is not surprising, considering the marginal impact of NAT onto survival; addressing a category of improved prognosis, we hypothesize that the relatively weak effect of NAT may not reveal itself on a limited sample size. Opposite results might also be explained by dissimilar sampling sizes (53 patients in the publication by Riquet et al. vs 309 in ours) leading to a lack of power. In addition, we have to be cautious about differences in patient selection and a potential Will Rogers effect. Our cohorts are not comparable; Riquet et al. divided their population into three categories: non-bulky N2 (below 2 cm, G2 group), bulky N2 (above 2 cm, G3 group) and micrometastases (G1 group). The authors did not detail criteria defining the latter group. Hence, we may speculate that G2 group, which harbours the best prognosis, may have included patients with N2 ranging from 0.2 to 2 mm, improving OS of this group. On the other hand, our non-micro-N2 group has included all the patients with metastasis >2 mm (including consequently G2 and G3 groups), which may change prognosis by an effect of different pooling.
Riquet et al. [3] argued that the adverse prognosis of micro-N2 is an argument for a more aggressive disease. However, micro-N2 is a necessary initial step leading to macroscopic N2, and its diagnosis cannot herald natural history of the disease. However, cancer cells harbouring EGFR mutations are higher responders to radiotherapy and chemotherapy [4] . We have shown in a subsequent study that micro-N2 is correlated with EGFR mutations (manuscript in preparation), which exhibits better prognosis in Caucasian surgical cohorts [4] .
In conclusion, prospective studies are necessary to evaluate the prognostic value of micro-N2.
Moreover, postoperative pain relief was even more successful than in epidural analgesia. Unfortunately, the Authors found no improvement of pain management in PVB. However, no meta-analysis was conducted, owing to limited data availability and a lack of uniformity in outcome measurement between studies with regard to the use of rescue analgesia and pain scores.
We support their conclusions with our present daily experience. In the last 2 years, we have definitively left epidural analgesia in favour of PVB by a catheter placed through the thoracotomy. Surgeons and anaesthetists achieve success using PVB analgesia at our thoracic surgery unit, because it is not only a safe and successful technique, but it is handy indeed.
These features make PVB very convenient for the anaesthetist who saves time preoperatively and for the surgeon who places the catheter at the end of the surgery in 5 mins.
As we have been satisfied with PVB analgesia, we decided to adopt it also in video-assisted thoracoscopic surgery (VATS) and developed a new technique for catheter placement which is simple and feasible during thoracoscopy [3] . Since in thoracoscopy, the posterior parietal pleura is always kept intact and any drug run-off in the pleural cavity is avoided, PVB in VATS is even more effective than in open surgery.
Prompted by our wish of innovation, we decided to use our VATS technique for paravertebral catheter placement [3] also in thoracotomies, leaving the technique adopted at the beginning [2] . Once again we were satisfied. At present, excluding cases of pleural disease, which is the only contraindication to catheter placement, we always use PVB in both VATS and thoracotomy.
We congratulate the Authors with the hope that their paper could be useful in focusing thoracic surgeons' attention on this successful analgesia.
The review written by Gonzalez-Rivas et al. [1] is delightful and informative on a recent and controversial topic: non-intubated thoracic surgery (NITS). As we all know, many of the current developments in different medical and surgical fields, e.g. minimally invasive, endovascular and others, are from proponents in Europe and Asia. Maybe, that is why American surgeons are reluctant to accept the evidence shown. At a recent conference at Duke in North Carolina, USA, Diego Gonzalez-Rivas presented his work and the audience of wellknown surgeons dismissed the idea about the inconvenience of having conscious patients in the operating room [2] .
Notwithstanding, Pompeo et al.'s [3] Survey of the European Society of Thoracic Surgeons showed a majority of respondents (59%) reported using non-intubated thoracic surgery procedures.
As we know, the NITS techniques are not new (they were described in the early 20th century) and remained useless for decades due to the intubated techniques, but the current research has demonstrated the feasibility, methods and good outcomes with NITS. Diego Gonzalez-Rivas said 'the NTIS techniques could be the standard managenement of a subset of patients otherwise inoperable, and in the future to everyone'. There will have to be multicentric clinical trials of NITS with enough power to convince the sceptical surgeons to adopt NITS for the well-being of thoracic patients worldwide.
